<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23372">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01899313</url>
  </required_header>
  <id_info>
    <org_study_id>2012.119-2</org_study_id>
    <nct_id>NCT01899313</nct_id>
  </id_info>
  <brief_title>A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence</brief_title>
  <official_title>A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Pacific Medical Center Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>California Pacific Medical Center Research Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I behavior therapy development study seeks to improve treatment outcomes for
      methamphetamine (MA)-dependent subjects by developing a novel cognitive behavioral therapy-
      (CBT-) based short message service (SMS) text messaging intervention.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of MA-negative urine samples between the 2-week CBT text period and the 2-week control period</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary efficacy measure for this study is the difference in proportion of MA-negative urine samples between the 2-week CBT text period and the 2-week control period. Urine samples will be analyzed for MA by immunoassay with a cutoff of 1,000 ng/mL.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Amphetamine-Related Disorders</condition>
  <arm_group>
    <arm_group_label>CBT- based SMS text messaging intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Texts</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo texts will be given instead of interventional texts</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT- based SMS text messaging intervention</intervention_name>
    <arm_group_label>CBT- based SMS text messaging intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT group therapy</intervention_name>
    <arm_group_label>CBT- based SMS text messaging intervention</arm_group_label>
    <arm_group_label>Placebo Texts</arm_group_label>
    <other_name>Cognitive Behavioral Group Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English-speaking adults â‰¥ 18 years who are seeking treatment for MA addiction.

          -  Own a cellular phone with SMS text messaging capability and have an unlimited text
             messaging plan.

          -  Available to attend CBT therapy groups.

          -  Agreeable to conditions of the study and signed an informed consent form.

        Exclusion Criteria:

          -  Projected to be unavailable &gt; 12 hours/day to read and send text messages.

          -  Any medical or psychosocial condition that would preclude safe, useful, or consistent
             participation,
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gantt Galloway, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Pacific Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen Garrison</last_name>
    <phone>415-600-3126</phone>
    <email>garrisk@cpmcri.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Reshmi Pal</last_name>
    <phone>415-600-1652</phone>
    <email>palrx@cpmcri.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New Leaf Treatment Center</name>
      <address>
        <city>Lafayette</city>
        <state>California</state>
        <zip>94549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Garrison</last_name>
      <phone>415-600-1652</phone>
      <email>garrisk@cpmcri.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addiction &amp; Pharmacology Research Laboratory</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen Garrison</last_name>
      <phone>415-600-1652</phone>
      <email>garrisk@cpmcri.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://nltc.com/</url>
    <description>clinical site at which patients are seen</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>May 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>California Pacific Medical Center Research Institute</investigator_affiliation>
    <investigator_full_name>Gantt Galloway, PharmD</investigator_full_name>
    <investigator_title>Senior Scientist</investigator_title>
  </responsible_party>
  <keyword>methamphetamine dependence</keyword>
  <keyword>texting</keyword>
  <keyword>short message service</keyword>
  <keyword>addiction</keyword>
  <keyword>amphetamine</keyword>
  <keyword>outpatient</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amphetamine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
